BrainStorm Cell Therapeutics (BCLI) shares rallied more than 30% on Thursday. The stock is gaining momentum ahead of Monday’s release of top-line data from a Phase 2 clinical trial evaluating lead product candidate NurOwn in patients with amyotrophic lateral sclerosis (ALS). Following the surge, BCLI shares are back to the levels they had been trading almost a year ago. The company though faces near-term dilution risk. It could use the surge in price to announce a secondary offering, especially if the data on Monday is positive.